Compare Stocks

→ How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
VIE Viela Bio	$53.01	$53.01	$25.02 ▼ $65.00	$2.91B	0.43	1.07 million shs	N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
VIE Viela Bio	0.00%	0.00%	0.00%	0.00%	0.00%

How to camouflage a factory of 53,000 workers (Ad)

"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."

Get the full story here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
VIE Viela Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
VIE Viela Bio	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
VIE Viela Bio	$50M	58.26	N/A	N/A	$7.14 per share	7.42

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
VIE Viela Bio	-$86.43M	-$7.02	N/A	N/A	N/A	N/A	-33.97%	-31.49%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
VIE Viela Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
VIE Viela Bio	N/A	19.51	19.49

Ownership

Institutional Ownership

Company	Institutional Ownership
VIE Viela Bio	46.98%

Insider Ownership

Company	Insider Ownership
VIE Viela Bio	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
VIE Viela Bio	166	54.95 million	N/A	Not Optionable

VIE, CLQ, and CWY Headlines

Source	Headline
	Novel Drug Made of Gold Nanocrystals Appears Safe in Multiple Sclerosis medpagetoday.com - April 22 at 3:07 PM
	FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) \| DelveInsight finance.yahoo.com - April 16 at 2:54 PM
	Mehr zu VIELA BIO INC. DL-,001 im Forum onvista.de - February 14 at 12:00 AM
	ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment benzinga.com - January 29 at 2:49 PM
	ArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024 bizjournals.com - January 27 at 3:29 AM
	ArriVent Biopharma Seeks $100 Million IPO For Lung Cancer Drug seekingalpha.com - January 9 at 2:41 PM
	ArriVent BioPharma Files For IPO marketwatch.com - January 5 at 8:54 PM
	Multiple sclerosis in 2023: beyond the boundaries thelancet.com - December 14 at 12:25 AM
	AstraZeneca Disputes Claims It Bullied Viela Bio into Sale news.bloomberglaw.com - December 12 at 7:27 PM
	This Week in Chancery Court: AstraZeneca Faces Bullying Claims news.bloomberglaw.com - December 11 at 8:31 AM
	Myasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] \| With CAGR of 7.5% finance.yahoo.com - December 6 at 12:06 PM
	Global CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key Players benzinga.com - November 17 at 2:50 PM
	Global CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of Therapies uk.finance.yahoo.com - November 9 at 9:52 AM
	Vitiligo: 'Impressive' Results for Povorcitinib and Baricitinib/NB-UVB in Phase 2 Trials medscape.com - November 8 at 5:29 PM
	CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Response Rates - ResearchAndMarkets.com pharmiweb.com - November 8 at 5:29 PM
	What's on the Horizon for Myasthenia Gravis medpagetoday.com - November 7 at 7:55 AM
	A Changing Treatment Landscape in Myasthenia Gravis medpagetoday.com - November 3 at 8:44 PM
	Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy finance.yahoo.com - November 3 at 10:43 AM
	Chutes & Ladders—J&J's medtech chief exits after almost 30 years fiercebiotech.com - October 27 at 2:25 PM
	Amgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for now bizjournals.com - October 25 at 7:50 PM
	Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer finanznachrichten.de - October 23 at 10:13 AM
	Score fluctuation might be associated with a higher placebo rate in the RAISE trial – Authors' reply thelancet.com - October 19 at 12:11 AM
	Analysis Spotlights Economic Burden of Vitiligo in the US medscape.com - October 11 at 6:56 PM
	Amgen gets Horizon acquisition over the line pharmaphorum.com - October 9 at 8:55 AM

Top Headlines

3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024 12:55 PM
View 3 Stocks Insiders Are Buying That Analysts Love
MarketBeat Week in Review – 3/25-3/29
March 30, 2024 7:00 AM
View MarketBeat Week in Review – 3/25-3/29
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money
MarketBeat Week in Review – 4/1 - 4/5
April 6, 2024 7:00 AM
View MarketBeat Week in Review – 4/1 - 4/5
MarketBeat Week in Review – 4/8 - 4/12
April 13, 2024 7:00 AM
View MarketBeat Week in Review – 4/8 - 4/12

All Headlines

Company Descriptions

Viela Bio

NASDAQ:VIE

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjÃ¶gren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial